Alzheimer’s disease (AD) is a neurodegenerative disease and the most cause of dementia in elderly adults. Acetylcholinesterase (AChE) is an important beneficial target for AD to control cholinergic signaling deficit. Centella asiatica (CA) has proven to be rich with active ingredients for memory enhancement. In the present study, the chemical profiling of three accession extracts of CA namely SECA-K017, SECA-K018, and, SECA-K019 were performed using high-performance liquid chromatography (HPLC). Four biomarker triterpene compounds were detected in all CA accessions. Quantitative analysis reveals that madecassoside was the highest triterpene in all the CA accessions. The biomarker compounds and the ethanolic extracts of three accessions were investigated for their acetylcholinesterase (AChE) inhibitory activity using Ellman’s spectrophotometer method. The inhibitory activity of the triterpenes and accession extracts was compared with the standard AChE inhibitor eserine. The results from the in vitro study showed that the triterpene compounds exhibited an AChE inhibitory activity with the half-maximal inhibitory concentration (IC50) values between 15.05 ± 0.05 and 59.13 ± 0.18 µg/mL. Asiatic acid was found to possess strong AChE inhibitory activity followed by madecassic acid. Among the CA accession extracts, SECA-K017 and SECA-K018 demonstrated a moderate AChE inhibitory activity with an IC50 value of 481.5 ± 0.13 and 763.5 ± 0.16 µg/mL, respectively from the in silico docking studies, it is observed that asiatic acid and madecassic acid showed very good interactions with the active sites and fulfilled docking parameters against AChE. The present study suggested that asiatic acid and madecassic acid in the CA accessions could be responsible for the AChE inhibitory action and could be used as markers to guide further studies on CA as potential natural products for the treatment of AD.

The evidence on the neuroprotective impact of Centella asiatica (C. asiatica) has been greatly documented in recent years. However, a major obstacle that remains to be overcome is the capacity of the active molecules in C. asiatica to cross the blood-brain barrier (BBB). In this study, we explored the possibilities of using a D-optimal mixture design to fabricate nanoemulsion of C. asiatica (NanoSECA) for better brain bioavailability. The parameters for optimization were the percentage of water (10–80% w/v) and virgin coconut oil (VCO) (10–80% w/v). Nanoemulsions were formulated using a high-pressure homogenization approach and were characterized for their physicochemical properties. The optimal VCO-based nanoemulsion (VBN: F2) conditions were found at 80% (w/v) of water and 10% (w/v) of VCO. Subsequently, viability tests were conducted on neuroblastoma (SH-SY5Y) and macrophage (RAW 264.7) cell lines. NanoSECA was distinguished for its antioxidant, acetylcholinesterase (AChE), anti-inflammatory, and parallel artificial membrane permeability assay (PAMPA) activities in vitro. The NanoSECA has a particle size of 127.833 ± 8.280 nm, zeta potential (ZP) of −24.9 ± 0.011 mV, polydispersity index (PDI) of 0.493 ± 4.681, percentage prediction error (PPE) of −12.02%, and pH of 6.0 ± 0.006 and is also stable under different storage conditions. Cell viability was improved in a dose-dependent manner on SH-SY5Y and RAW 264.7 cell lines. In addition, NanoSECA significantly reduced the AChE activity, suppressing the level of proinflammatory mediators and oxidative stress. Moreover, NanoSECA showed high BBB permeation with a high value of experimental permeability to cross the BBB. Thus, NanoSECA could efficiently potentiate the central nervous system (CNS) therapeutic activities through enhanced penetration of BBB. These nano-delivery systems are crucial to unlock the full potential of C. asiatica for treating numerous CNS disorders.

Background: In recent years, the potential role of probiotics has become prominent in the discoveries of neurotherapy against neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Lactic acid bacteria (LAB) exhibit neuroprotective properties and exert their effects via various mechanisms of actions. This review aimed to evaluate the effects of LAB on neuroprotection reported in the literature. Methods: A database search on Google Scholar, PubMed, and Science Direct revealed a total of 467 references, of which 25 were included in this review based on inclusion criteria which comprises 7 in vitro, 16 in vivo, and 2 clinical studies. Results: From the studies, LAB treatment alone or in probiotics formulations demonstrated significant neuroprotective activities. In animals and humans, LAB probiotics supplementation has improved memory and cognitive performance mainly via antioxidant and anti-inflammatory pathways. Conclusions: Despite promising findings, due to limited studies available in the literature, further studies still need to be explored regarding synergistic effects, efficacy, and optimum dosage of LAB oral bacteriotherapy as treatment or prevention against neurodegenerative diseases.

No abstract

Neuroinflammation and deficiency of cholinergic are major factors of neurodegenerative damage correlated to cognitive impairment in Alzheimer’s disease (AD). We investigated the anti-inflammatory and anti-acetylcholinesterase activities of apple and date vinegars added with Centella asiatica in SH-SY5Y neuroblastoma cells. The neuroprotective effect of apple or date vinegar added with various percentage of C. asiatica (0, 0.5, 2, 5) % w/v was determined in vitro. The methanolic extract of apple vinegar added with 2% C. asiatica (AV-2% CA) and date vinegar added with 2% C. asiatica (DV-2% CA)  extracts showed potent neuroprotective effect. Both extracts were subjected to liquid-liquid partitioning yielded aqueous (H2O: AV/DV-2% CA) and ethyl acetate (EA: AV/DV-2% CA) extracts. Anti-inflammatory response against nitric oxide (NO) of all extracts was measured in LPS-induced SH-SY5Y neuroblastoma cells and percentage inhibition of acetylcholinesterase (AChE) was measured using commercially available test kits. It was found that EA: DV-2% CA showed potent ameliorating effect against LPS-induced inflammation (I50: 563.5 ± 0.13μg/mL) and was also responsible in the AChE inhibition activity (IC50: 9.087 ± 0.02). Thus, this extract is suggested to have dual properties of anti-inflammatory and anti-acetylcholinesterase inhibition activity that could be beneficial in the treatment and prevention of neurodegenerative disease.